Patent · US Active

Interferon therapy

US10335461B2 · kind B2 · utility

0Cited by
2References
16Claims
0Family size

Assignee

Inventor

Key dates

Filing dateFeb 11, 2017
Grant dateJul 2, 2019
Priority date—
Expiry dateFeb 11, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2710/10343
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Interferon therapy is improved by concomitant administration of an agent which minimizes the ability of interferon to up-regulate expression of Programmed Cell Death Protein 1 (also known as CD279).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.